Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$36 Mln
P/E Ratio
--
P/B Ratio
6.03
Industry P/E
--
Debt to Equity
-11.16
ROE
-5.56 %
ROCE
-91.75 %
Div. Yield
0 %
Book Value
--
EPS
-1.24
CFO
$-324.85 Mln
EBITDA
$-361.17 Mln
Net Profit
$-449.43 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Iterum Therapeutics PLC (ITRM)
| -38.98 | -21.74 | -29.87 | -25.52 | -38.32 | -50.03 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Iterum Therapeutics PLC (ITRM)
| 134.52 | -85.71 | -60.36 | -78.02 | -10.18 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 27.02 | 4,483.54 | 12.36 | 27.52 | |
| 9.10 | 557.63 | -- | -19.58 | |
| 9.20 | 498.44 | -- | -23.34 |
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of... uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Address: 3 Dublin Landings, Dublin, Ireland, D01 C4E0 Read more
President, CEO & Director
Mr. Corey N. Fishman
President, CEO & Director
Mr. Corey N. Fishman
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Iterum Therapeutics PLC (ITRM) stood at $ 45 Mln as on 31-Dec-24
The share price of Iterum Therapeutics PLC (ITRM) is $1.08 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Iterum Therapeutics PLC (ITRM) has given a return of -38.32% in the last 3 years.
Iterum Therapeutics PLC (ITRM) has a market capitalisation of $ 36 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Iterum Therapeutics PLC (ITRM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Iterum Therapeutics PLC (ITRM) and enter the required number of quantities and click on buy to purchase the shares of Iterum Therapeutics PLC (ITRM).
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Address: 3 Dublin Landings, Dublin, Ireland, D01 C4E0
The CEO & director of Mr. Corey N. Fishman. is Iterum Therapeutics PLC (ITRM), and CFO & Sr. VP is Mr. Corey N. Fishman.
There is no promoter pledging in Iterum Therapeutics PLC (ITRM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
501
|
|
|
76
|
|
|
45
|
|
|
501
|
| Iterum Therapeutics PLC (ITRM) | Ratios |
|---|---|
|
Return on equity(%)
|
472.61
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Iterum Therapeutics PLC (ITRM) was $0 Mln.
$0.03
(
